A randomized, double-blind, multi-centre to evaluate the efficacy and safety of adding mirabegron to solifenacin in incontinent OAB subjects requiring additional relief for their OAB symptoms (The BESIDE Study)

Trial Profile

A randomized, double-blind, multi-centre to evaluate the efficacy and safety of adding mirabegron to solifenacin in incontinent OAB subjects requiring additional relief for their OAB symptoms (The BESIDE Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Mirabegron (Primary) ; Solifenacin
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms The BESIDE Study
  • Most Recent Events

    • 29 Aug 2014 Status changed from recruiting to active, no longer recruiting as compared by ClinicalTrials.gov record.
    • 23 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top